Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR23303731

—

37cd779d-6ead-5019-98bc-6dc79c527312

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
  • HEDGEHOG_SIGNALING+0.450
  • HYPOXIA+0.430
  • IL6_JAK_STAT3_SIGNALING+0.410
  • ANGIOGENESIS+0.370
  • INTERFERON_ALPHA_RESPONSE+0.370
  • ALLOGRAFT_REJECTION+0.360
  • APICAL_JUNCTION+0.360
  • INTERFERON_GAMMA_RESPONSE+0.350
  • MYOGENESIS+0.350

Top 10 suppressed

  • MYC_TARGETS_V1-0.610
  • OXIDATIVE_PHOSPHORYLATION-0.530
  • E2F_TARGETS-0.500
  • PROTEIN_SECRETION-0.460
  • G2M_CHECKPOINT-0.450
  • MTORC1_SIGNALING-0.390
  • FATTY_ACID_METABOLISM-0.320
  • MYC_TARGETS_V2-0.310
  • PEROXISOME-0.300
  • CHOLESTEROL_HOMEOSTASIS-0.270

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1AUR-AER2-TTM3-A-1-1-R-A742-41
breast-umap@18
—D0.929
2DRR168555
bladder-landscape@3
——0.919
3SRR35579837
breast-umap@18
—D0.916
4SRR8613743
breast-umap@18
—D0.911
520120155.TNBC
breast-umap@18
—D0.904
6TCGA-63-7022-01A-11R-1949-07
lung-landscapes@6
—cohortSQ10.902
7BSR_12_0273_A5_S86
breast-umap@18
—A0.902
8TCGA-C8-A8HR-01A-11R-A36F-07
breast-umap@18
—A0.899
9TCGA-AC-A3W6-01A-12R-A22K-07
breast-umap@18
—A0.897
10R139
bladder-landscape@3
——0.897

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.530Inavolisib— uncovered
HEDGEHOG_SIGNALING0.450Inavolisib— uncovered
HYPOXIA0.430Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.410Inavolisib— uncovered
ANGIOGENESIS0.370Remibrutinib— uncovered
INTERFERON_ALPHA_RESPONSE0.370Inavolisib— uncovered
ALLOGRAFT_REJECTION0.360Idelalisib— uncovered
APICAL_JUNCTION0.360Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.350Idelalisib— uncovered
MYOGENESIS0.350Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.330Inavolisib— uncovered
COAGULATION0.320Binimetinib— uncovered
INFLAMMATORY_RESPONSE0.310Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.280Inavolisib— uncovered
COMPLEMENT0.260Inavolisib— uncovered
IL2_STAT5_SIGNALING0.260Idelalisib— uncovered
MITOTIC_SPINDLE0.190Inavolisib— uncovered
NOTCH_SIGNALING0.190Inavolisib— uncovered
UV_RESPONSE_DN0.130Inavolisib— uncovered
KRAS_SIGNALING_UP0.120Inavolisib— uncovered